Skip to main content
OpenTrials

Clinical trial condition

Herpes Zoster

Explore clinical trials studying Herpes Zoster. Study availability and eligibility vary by location and protocol.

174 public trials 19 recruiting studies
Refine in advanced search Browse all conditions

Herpes Zoster trial results

Completed

Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

NCT02075515

Conditions
DNA Virus Infections, Herpes Zoster, Herpes Zoster Vaccine, +4 more
Locations
  • GSK Investigational Site Mesa, Arizona, United States
  • GSK Investigational Site Wichita, Kansas, United States
  • GSK Investigational Site Milford, Massachusetts, United States
  • GSK Investigational Site Ghent, Belgium
View Trial Details
Completed

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

NCT02045836

Conditions
DNA Virus Infections, Herpes Zoster, Herpes Zoster Vaccine, +4 more
Locations
  • GSK Investigational Site Golden, Colorado, United States
  • GSK Investigational Site Wichita, Kansas, United States
  • GSK Investigational Site Columbia, Maryland, United States
  • GSK Investigational Site Coquitlam, British Columbia, Canada
View Trial Details
Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy

NCT01798056

Conditions
DNA Virus Infections, Herpes Zoster, Herpes Zoster Vaccine, +4 more
Locations
  • GSK Investigational Site Halifax, Nova Scotia, Canada
  • GSK Investigational Site Toronto, Ontario, Canada
  • GSK Investigational Site Montreal, Quebec, Canada
  • GSK Investigational Site Prague, Czechia
View all 28 locations
View Trial Details
Completed

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

NCT02690207

Conditions
DNA Virus Infections, Herpes Zoster, Herpesviridae Infections, +3 more
Locations
  • GSK Investigational Site Mesa, Arizona, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Phoenix, Arizona, United States
View all 195 locations
View Trial Details
Completed

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

NCT01165177

Conditions
DNA Virus Infections, Herpes Zoster, Herpesviridae Infections, +3 more
Locations
  • GSK Investigational Site Mesa, Arizona, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Phoenix, Arizona, United States
View all 274 locations
View Trial Details

Related conditions